MILLICENT STETTLER: Open Payments
NPI 1609452986 · MANASSAS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,318 in 68 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $702 · 2025 $1,318
Food & beverage: $1,318
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 18 | $230 |
| Dexcom, Inc. | 3 | $158 |
| E.R. Squibb & Sons, L.L.C. | 9 | $148 |
| Novo Nordisk Inc | 10 | $146 |
| Lilly USA, LLC | 6 | $130 |
| GlaxoSmithKline, LLC. | 5 | $103 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $89 |
| AstraZeneca Pharmaceuticals LP | 4 | $82 |
| Exact Sciences Corporation | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
Products named: ELIQUIS, DEXCOM G7 GSS (161), CAMZYOS, MOUNJARO, Kerendia, TRELEGY ELLIPTA, Rybelsus, Ozempic.
Industry payments across VA — which companies pay providers there.
